NeuroPace (NASDAQ: NPCE), is growing the implantable device market for treating drug-resistant focal epilepsy and setting itself up to dominate it for years to come. With an offering that provides better outcomes than its competition, significant penetration into epilepsy centers across the U.S., and potential label expansions that could just about double its current addressable market, this company could offer significant upside to investors.